Advanced MRI techniques, such as MR spectroscopy, diffusion and perfusion MR imaging can give important in vivo physiological and metabolic information, complementing morphologic findings from conventional MRI in the clinical setting. Combining perfusion MRI and MR spectroscopy can help in patients with brain masses in who the pre-operative differential diagnosis is unclear. This review demonstrates the use of dynamic, susceptibility weighted, contrast-enhanced MR imaging (DSC MRI) and magnetic resonance spectroscopic imaging (MRSI) to distinguish surgical from non-surgical lesions in the brain. There is overlap in the MRI appearance of many enhancing and ring-enhancing lesions such as gliomas, metastases, inflammatory lesions, demyelinating lesions, subacute ischemia, abscess and some AIDS related lesions. We review examples of histopathologically confirmed high-grade glioma, a middle cerebral artery territory infarct, a tumefactive demyelinating lesion and a metastasis for which conventional MR imaging (MRI) was non-specific and potentially misleading and demonstrate how DSC MRI and MRSI features were used to increase the specificity of neurodiagnosis.
Introduction
Conventional MRI provides exquisite anatomic delineation of intracranial pathology. However, on occasion it has lead a radiologist or surgeon to misdiagnosing lesions which should have been treated conservatively rather than surgically. This has tremendous impact not only on the patient and physician but on the cost and efficiency of healthcare delivery. We are using four lesions from our collection presenting with similar conventional MRI findings to illustrate the clinical utility of MRSI and DSC MRI. The MRI findings were sufficiently suggestive of tumor to lead to surgical intervention. At histopathological examination only two of the four lesions was confirmed to be tumor while the other two were proved to be a middle cerebral artery territory infarct and a tumefactive demyelinating lesion (TDL). Supplementing anatomic information with physiologic and metabolic information from perfusion MR imaging and proton MR spectroscopy ( 1 H-MRS) increases sensitivity and specificity in neuro-diagnosis, avoiding unnecessary surgery (1).
Techniques

Proton MR Spectroscopic Imaging (MRSI)
Proton MRSI is a sensitive advanced MRI technique that has become a part of routine clinical imaging in many institutions. Spectroscopy provides estimates of the concentration of several metabolites (2) (3) (4) (5) (6) and is useful as a non-invasive means of studying the biochemistry of a lesion relative to normal brain. MRSI provides reproducible data on brain chemistry in relatively short acquisition and processing times. Single voxel spectroscopy techniques, which interrogate a single volume of tissue, have often been used but are not ideal for large heterogeneous lesions because volume averaging over large voxels may yield data that may misrepresent a lesion. MR Spectroscopic Imaging (MRSI) (also called chemical shift imaging, CSI), which divides large regions of interest (ROI) into smaller voxels, thus providing a crude image of the different metabolites, is more appropriate for the study of large heterogeneous regions. MRSI generates a large dataset which provides measurements throughout heterogeneous lesions and also allows comparison of pathologic voxels with contralateral normal appearing brain tissue (7-9).
Dynamic Susceptibility Contrast Perfusion MRI (DSC MRI)
DSC MRI allows for the simultaneous calculation of rCBV, CBF, MTT, TTP (time to peak) and vascular permeability with reasonable spatial resolution within a lesion. These values are calculated from the first pass of contrast bolus during T2* weighted gradient echo imaging (1, 7, (10) (11) (12) (13) . DSC MRI generally provides better signal to noise ratio than alternative techniques based on arterial spin labeling (14) but does have some disadvantages: Measurements may be inaccurate in lesions with severe BBB breakdown and susceptibility artifacts near a bone/brain interface, or in the vicinity of a large vessel, can prevent measurements in some areas (11).
Clinical Utility of DSC MRI and MRSI
High Grade Glioma
A 70-year-old female without significant past medical history presented with left sided paraesthesia. MRI showed a ring-enhancing irregular mass in the right temporal region extending to the thalamus/basal ganglia (Figure 1 ). DSC MRI demonstrated elevated rCBV, CBF and decreased MTT. MRSI demonstrated marked Cho elevation with respect to Cr and NAA from the tumoral and peritumoral regions indicating a high grade glioma with tumor infiltration into the surrounding tissues. The combination of increased perfusion and increased Cho in the tumoral and peritumoral regions is consistent with a high-grade glioma. The patient underwent intra-operative frozen section diagnosis which suggested a high-grade glioma and aggressive surgical resection was performed. The final histopathological diagnosis was anaplastic astrocytoma.
Acute to Subacute Infarct
A 45-year-old female presented with a 10 day history of sudden onset right sided upper and lower extremity weakness. MRI demonstrated an irregularly enhancing mass in the left fronto-temporal region with edema and slight mass effect. The conventional images were highly suggestive of a mass lesion ( Figure 2 ). This was discordant with the clinical history of abrupt symptom onset. Diffusion-weighted imaging was performed and demonstrated heterogeneous diffusion with some areas of high signal (diffusion restriction and areas of low signal, a pattern seen in some gliomas and subacute evolving infarcts). DSC MRI color overlay maps indicated reduced CBF and prolonged MTT within the left hemisphere. MRSI demonstrated an increase in Cho/Cr within the abnormal voxels in the left hemisphere, however there was an overall decrease in metabolites (Cho, NAA and Cr) when compared with the right hemisphere, indicating reduced metabolism. There is also increased lipid and lactate from anerobic glycolysis and demyelination. The patient underwent stereotactic biopsy to rule out tumor rather than resection, as the lesion still appeared suspicious for tumor on MRI. The final histopathological diagnosis was a left middle cerebral artery (MCA) infarct.
Tumefactive Demyelinating Lesion
A 57-year old male, without any significant past medical history presented with recurrent headache. MRI revealed a peripherally enhancing mass in the frontal lobe bilaterally in a "butterfly configuration" suggestive of a high-grade glioma ( Figure 3 ). DSC MRI demonstrated reduced rCBV throughout the lesion. MRSI showed an increase of the Choline (Cho) peak and a slight decrease of the N-acetylaspartate (NAA) peak. The Cho/Cr and Cho/NAA ratios were elevated but not as much as would usually be seen in a high-grade glioma. The patient went to surgery (right frontal lobectomy) for a presumptive diagnosis of a "butterfly glioma" or glioblastoma multiforme. The final histopathological diagnosis was a tumefactive demyelinating lesion (TDL).
Metastases 60 year-old-woman with a history of primary breast carcinoma. MRI shows a well defined mass in the left frontal region with a target-like appearance and negligible edema surrounding this lesion. On MRSI there is Cho/Cr elevation within the tumor and in voxels where there is partial volume averaging with the tumor. However, the MRSI spectral map demonstrates no elevation in Cho within voxels in the peri-tumoral region of the lesion, indicating a non-infiltrating lesion like a metastasis. Gradient-echo axial DSC MRI with rCBV color overlay may demonstrating increase in tumor vascularity confined to the enhancing tumor but not within the peritumoral region ( Figure 4 ). Given that it was a solitary metastasis, it was resected and proven to be a breast metastasis.
Other non-surgical options may include gamma-knife radiosurgery or chemotherapy if it was a chemosensitive lesion.
Discussion: Surgical or Non-Surgical Lesions
High-Grade Glioma vs Stroke
Conventional MR images of stroke and glioma may demonstrate similar contrast enhancement, mass effect, T2 signal abnormality, hemorrhage, and border definition findings. For example, both types of lesion show varying degrees of blood brain barrier (BBB) disruption and contrast enhancement. The degree of BBB breakdown may be a function of the mechanism of endothelial proliferation associated with the lesion in the case of tumor, since each mechanism can have a characteristic impact on vascular permeability (13). The degree of BBB disruption in stroke is variable and may not correlate directly with the extent of ischemia, but may rather be influenced by factors including duration of ischemia, existence and duration of reperfusion, hyperemia, and neuronal damage (15) (16) (17) . Due to this variability, contrast enhancement is sometimes not helpful in distinguishing infarct from tumor. Diffusion-weighted imaging is extremely sensitive and time efficient in demonstrating acute ischemia and infarction (18) . However in the setting of a subacute stroke, the diffusion and apparent diffusion coefficient measurements may begin to normalize, resulting in a heterogenous diffusion image, sometimes seen in both subacute strokes and also in very heterogeneous tumors.
Previous studies have shown that certain types of lesions demonstrate characteristic metabolic and perfusion findings (6, 10, (19) (20) (21) (22) . MRSI of stroke generally shows elevated Choline to Creatine ratio (Cho/Cr) due to cell membrane destruction and demyelination. However there is an overall decrease in choline with respect to normal contralateral choline levels [Cho/Cho(n)] suggesting that the elevated Cho/Cr ratio is due to a decrease of Cr rather than to an absolute increase of Cho. Lactate is also demonstrated for up to 6 weeks and sometimes beyond, initially from anaerobic glycolysis, then later from macrophage activity and persistent ischemia (9). In addition, after infarct, as brain metabolism decreases, the neuronal marker N-Acetyl-Aspartate (NAA), and Cr progressively decline resulting in a decrease in NAA/NAA(n) and Cr/Cr (n) (9). Cr, as an energy marker, is particularly reduced in stroke. Using short echo MRSI, the glutamine/glutamate (Glx) metabolites may also be elevated in an infarct. MRSI in high-grade gliomas also shows elevated Cho/Cr, lipids and lactate from necrosis, and decreased NAA ( Figure 1 ). Importantly, overall Cho/Cho(n), i.e., Cho relative to the contralateral normal Cho will be substantially elevated in accordance with the increased turnover of the tumor cells and increased cellular density in comparison to normal tissue (2, 5, 6, 20, (23) (24) (25) (26) (27) . Lipid and lactate may also be present in a glioma. The perfusion MR and MR spectroscopic findings that differentiate high-grade glioma from stroke are summarized in Table I . ) ] is less than the contralateral control Cho (n), indicating an ischemic rather than neoplastic process. L, MRSI (TE 144ms) with the vertical scale uncorrected (red circle), demonstrating the pitfall of reading a spectrum without a contralateral control. Finding substantial reduction in all metabolites (Cr, Cho and NAA) by comparing a spectrum with the normal contralateral control can increase the specificity and exclude a neoplastic process in favor of infarct in this case.
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Figure 3: 57-year-old-man with a tumefactive demyelinating lesion (TDL).
A, Axial T1-weighted image post gadolinium in the stereotactic head frame, shows a peripherally enhancing mass in the frontal regions with involvement of the corpus callosum. The mass like appearance and "butterfly" configuration prompted the neurosurgeon to stereotactic surgical resection. The histopathology was a TDL. B, Gradient-echo axial DSC MRI with rCBV color overlay demonstrating reduced vascularity within the lesion, even at the enhancing so-called "leading" edge. Prominent vessel-like structures (veins) are identified within the lesion. These TDLs are known to arise along vascular or venular structures. C, MRSI (TE 30ms) demonstrated increased Cho and decreased NAA, with some lipid and lactates. However, the degree of decrease in NAA is not as substantial as that found in a glioma. It is thought that the degree of neuronal loss or replacement is not a great as with a glioma. D, Comparison is made with MRSI (TE 144 ms) from a highgrade glioma demonstrating increased Cho and lactate, however note that there is much more substantial decrease in NAA than in a TDL. increase in vessel number and cross sectional area is consistent with the increase in cerebral blood volume measurements made with DSC MRI.
Gliomas, particularly high-grade gliomas will typically have significantly elevated rCBV (and decreased MTT) (1). An acute stroke will demonstrate decreased CBF and increased MTT, findings demonstrated to be sensitive indicators of ischemia/infarct by a number of investigators (28, 30, (32) (33) (34) Table I .
High-Grade Glioma vs Tumefactive Demyelinating Lesion (TDL)
In differentiating tumor from TDL, interpretation of MRI findings can sometimes be difficult. Previous studies have described the potential similarities in conventional images and even the similar histopathologic findings of tumor and TDL. Both lesions may exhibit variable contrast enhancement, perilesional edema, varying degrees of mass effect, and central necrosis (35) (36) (37) . In particular, some highgrade gliomas show minimal edema and mass effect, clear border definition, variable contrast enhancement, and are confined to white matter, findings atypical of high-grade gliomas. At the same time TDL may present as a solitary, large lesion with enhancement, central necrosis, perilesional T2-signal abnormality, and mass effect more typically associated with neoplasm than TDL. The management of the two lesions is entirely different.
TDL is a non-surgical lesion. Stereotactic biopsy may be misleading because of the small biopsy sample size and certain similarities in appearance on histopathologic assessment. These include the presence of hypercellularity, reactive astrocytes, mitotic figures, and areas of necrosis. Stains for myelin and axons can sometimes help distinguish between TDL and tumor (35). DSC MRI can help differentiate tumors and TDLs. TDLs are devoid of true angiogenesis, and therefore they do not demonstrate a marked change in rCBV, CBF or MTT (35). Cha et al. found a mean rCBV of 0.88 for a group of TDLs (n=12) with nonspecific conventional imaging. In contrast, as described above, tumors are characterized by neovascularization and angiogenesis that contribute to a significant elevation in rCBV. The same study found a mean rCBV of 6.47 in the tumor group (n=11). The difference in rCBV of the two groups was statistically significant.
Relative CBV data can complement MRI and clinical presentation to help distinguish tumors from TDLs. A markedly elevated rCBV would increase the likelihood that a lesion is a tumor rather than a TDL. However it is important to be cautious in applying these findings in each case. Despite the statistical significance of the difference between the two groups' mean rCBV, the ranges did overlap and any given case could be one of these outliers. For example, an rCBV measurement of 1.6 would not be conclusive.
Another imaging finding is the vasocentricity of TDLs. Primary demyelinating plaques have a propensity to form around and adjacent to venous structures (35). This is best visualized either on a post contrast T1-weighted image ( Figure 3A) or by reviewing the serial images from a perfusion dataset acquired over a time course when marked signal intensity loss is seen within venules running through the central portion of a large TDL. TDL will form around a vein, however a glioma will tend to invade, displace and recruit vascular structures. This central (signal) loss in TDL is due to slow flowing blood in the vein resulting in susceptibility effects and a drop of signal intensity in TDLs.
In comparing MR spectroscopy between TDLs and highgrade gliomas, there is some overlap in the appearance of the spectra. There is Cho elevation in TDLs from astrogliosis, demyelination and inflammation; a lactate peak exists due to local anaerobic glycolysis, neuronal mitochondrial dysfunction and inflammation and there is a decrease in NAA from neuronal and axonal damage (38) (39) (40) (41) . However, the NAA/Cr ratio is higher in both the enhancing region and central region of TDLs compared to high-grade gliomas, where there is substantial neuronal destruction and replacement. It may also be useful to perform short echo time MRSI. In cases of demyelinating lesions, Myo-inositol is typically high but it is low in high-grade gliomas. Hence the combination of reduced perfusion, increased Myo-inositol and moderate NAA reduction can help differentiate the TDL from high-grade glioma (36, 37) Table I .
Tumefactive Demyelinating Lesion vs Stroke
The possibility also exists that TDL and stroke might be confused in the clinical setting. The perfusion parameters might not distinguish these two lesions: Relative CBV is variable in stroke so that this parameter alone is not specific (32, 33) . MTT is elevated in stroke and mildly elevated in TDL. Neither of these parameters is therefore specific. However, CBF is normal in TDL and decreased in stroke so may help to distinguish the two lesions (Table I) . 1 H-MRS is able to distinguish the TDL from stroke. As in glioma, Cho/Cho(n) is elevated in TDL due to the demyelination whereas the ratio is decreased in infarct (9). Additionally, the various metabolite ratios (Table I) considered together suggest that stroke exhibits a greater decrease in NAA than does TDL. In other words, stroke NAA/NAA(n) is expected to be less than TDL NAA/ NAA(n). This MRSI data helps in distinguishing TDL from stroke (Figure 3) . Importantly, conventional MRI appearances of stroke usually conforms to a vascular territory whereas a TDL often does not demonstrate a vascular distribution. This underscores the importance of considering all available imaging as well as clinical findings, to optimize the diagnosis. The neuroradiologist and neurosurgeon are often presented with diagnostic challenges. A patient with ring-enhancing mass presents a number of differential diagnoses. Tumoral disease such as a high-grade glioma warrants surgical intervention. In contrast, there are a number of "do not touch" lesions which are optimally managed with watchful waiting such as a tumefative demyelinating lesion or stroke.
High Grade Glioma vs Metastases
A solitary brain metastases may be indistinguishable from a primary glioma by conventional MRI imaging. The intratumoral MRSI and rCBV is also not able to reliably differentiate between the metastases and glioma. Metastases typically demonstrate variable elevations of Cho, lactate and lipids. NAA is low or absent in metastases in keeping with the lack of neuroglial elements (5). Finding NAA in a voxel over a metastatic lesion is usually due to partial volume effects with adjacent normal brain. A number of investigators initially differentiated metastases from gliomas by demonstrating the presence of lipid/ lactate peaks (0.9-1.5 ppm) in metastatic lesions but not in high-grade gliomas at both short (TE 20 ms) and intermediate echo time (135/144 ms) (42-44) as well as a lack of Cr in metastases (44). However, in areas of central necrosis in high-grade gliomas, there is also often lipid and lactate, as well as a lack of Cr, so the intratumoral spectrum is often non-specific.
The differences in the pathophysiology of the peri-tumoral region of gliomas and metastases results in differences in rCBV and Cho, which can differentiate between these two pathologies. High-grade gliomas are known to be infiltrating tumors, with tumoral tissue infiltrating along vascular channels, whereas in metastases the peri-tumoral region contains no infiltrating tumors cells or vascular endothelial proliferation and is almost purely vasogenic edema (45, 46) . In differentiating glioma from metastases, finding high Cho and high rCBV in the peri-tumoral region of a lesion ( Figure  4) is more likely to represent a glioma rather than a metastases (7) ( Table I) . Determination that a lesion may be metastatic rather than a high-grade glioma may change therapy in many ways. A solitary metastasis may be amenable to gamma-knife radiosurgery; a chemosensitive metastasis may be treated medically, and finally a patient with diffuse whole body metastases will be treated conservatively.
For the neurosurgeon, pre-operative differentiation of surgical from non-surgical disease is of paramount importance. Every surgical procedure, no matter how minor, carries a risk of neurologic impairment. Even stereotactic brain biopsy carries a 1-2% risk of hemorrhage with possible deficit. Craniotomy with tumor resection carries higher risks depending on the cortical areas involved and the surgical approach. If the neurosurgeon can confidently replace a craniotomy for resection with a stereotactic biopsy for diagnosis, significant risk can be averted. If the neurosurgeon can forego surgical procedure altogether based on characteristic advanced MRI imaging findings, surgical risk can be avoided altogether.
The ultimate goal will be to avoid diagnostic procedures altogether, relying instead on the imaging findings for diagnosis. Surgery can then be limited to resections intended to provide relief of mass effect, cytoreduction, and, in the case of benign disease, such as a meningioma, cure.
Conclusion
Combining advanced MRI techniques like MRSI with DSC MRI can increase sensitivity and specificity in neuro-diagnosis. The ability to pre-operatively confirm a diagnosis of a non-surgical lesion such as a TDL or stroke will no doubt avoid substantial morbidity, cost and potential mortality associated with neurosurgical intervention and concomitant radiation or chemotherapy.
DSC MRI and MRSI techniques are gaining favor in the clinical setting for glioma grading, monitoring anti-angiogenic therapy (47, 48) , and guiding stereotactic biopsy. They also can be useful in outcome prediction, the detection of salvageable tissue, and in differentiating between therapy related changes and recurrent tumor.
